In patients with ischemic stroke, NVAF, and ASCVD, adding an antiplatelet to OAC therapy did not affect net clinical benefit at 2 y

Annals of Internal Medicine 2026

View at publisher

Authors: Mukul Sharma, Abhilekh Srivastava

DOI: 10.7326/annals-25-05308-jc

Cited by: 0

References: 3

Abstract

CLINICAL IMPACT RATINGS: GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text] Hematology: [Formula: see text].

Atrial Fibrillation Management and Outcomes Acute Ischemic Stroke Management Antiplatelet Therapy and Cardiovascular Diseases

References 3